Jennewein Biotechnologie: First clinical trial of a blend of human milk oligosaccharides emulating the human profile of infant formula (FOTO)

Rheinbreitbach (ots) -

Jennewein Biotechnologie GmbH announces its first clinical trial
of an infant formula that contains human milk oligosaccharides at the
concentrations naturally found in human breast milk.

Jennewein Biotechnologie is a leading producer of complex
oligosaccharides, focusing on human milk oligosaccharides (HMOs). In
July 2018, Jennewein Biotechnologie will launch its first clinical
trial of an infant formula containing the five most abundant neutral
and acidic HMOs at their natural concentrations, closely replicating
the composition of human breast milk HMOs do not provide energy for
infants, but instead perform many beneficial functions such as
promoting the growth of beneficial gut bacteria, blocking pathogens,
and stimulating brain development. The ability of HMOs to support
beneficial gut bacteria (the human gut microbiome) is important
because such bacteria not only inhibit pathogens but also coordinate
with the body to reduce the risk of allergies and chronic diseases
such as irritable bowel syndrome and obesity later in life.

This primary purpose of the clinical trial is to confirm the
nutritional suitability and tolerability of the HMO mixture for
infants, which is a pre-requisite for the registration of the new
product as a novel food ingredient under EU regulations
(EU2015/2283). The clinical trial will be carried out in Austria,
Germany, Italy and Spain.

A secondary purpose is to compare the development of the gut
microbiome in infants fed on formula with and without HMOs. The gut
microbiome is now a key research topic, reflecting the development of
new technologies that make it easier to characterize the composition
and functionality of complex microbial communities. Jennewein
Biotechnologie hopes to provide their customers and partners with
greater insight into the prebiotic effects of HMOs and how these
contribute to a healthy gut microbiome.

"This is a major step forward in our mission to close the gap
between human breast milk and infant formula" says Stefan Jennewein,
CEO and founder of Jennewein Biotechnologie GmbH.

Jennewein Biotechnologie GmbH was founded in 2005 with the vision
to develop new production processes for complex oligosaccharides. The
company manufactures an extensive portfolio of HMO's such as for
example 2'-Fucosyllactose, 3'-Fucosyllactose or Lacto-N-tetraose.
These HMO's are for medical and nutritional application.

They are produced using the latest fermentation technology. The
production process is based in scientific research.

Jennewein received in 2015 approval in the US (GRAS) and in 2017
novel food authorization for 2'-Fucosyllactose in the European Union.

Contact:
For further information please contact Bettina Gutierrez,
bettina.gutierrez@jennewein-biotech.de, +49 2224-9197346

Original-Content von: Jennewein Biotechnologie GmbH, übermittelt durch news aktuell